Dive Brief:
- AbbVie said its dual-acting drug for multiple myeloma met the main goal of a Phase 3 clinical trial, helping people who’ve progressed on two or more lines of therapy survive longer without progression than those who received standard treatment regimens, the company said Thursday.
- The drug, called etentamig, could be safer than rival drugs launched by Johnson & Johnson, Pfizer and Regeneron, with low rates of two kinds of serious immune responses common to other drugs of its type. AbbVie said its safety profile could enable greater use in community oncology centers because of reduced need for post-treatment patient monitoring.
- Etentamig is a type of drug called a bispecific antibody that can simultaneously bind to diseased tumor cells and T cells, triggering an immune response to fight multiple myeloma. It trails by more than four years the first drug in its class, J&J’s Tecvayli, which booked $462 million in sales through the first six months of 2026.
Dive Insight:
Immunotherapy has reshaped care across nearly every type of cancer, and the blood cancers like leukemia, lymphoma and multiple myeloma have been part of that transformation. In blood cancers, it first started with a type of engineered cell treatment called CAR-T therapy, and dual-acting bispecific antibodies have followed closely behind.
Bispecific antibodies have an advantage against CAR-T therapies, which require extensive re-engineering of patients’ own cells to fight cancer. But they still carry some of the same safety issues, specifically immune responses called cytokine release syndrome and a neurological condition called ICANS, which have required similar post-treatment monitoring protocols that patients who receive CAR-T therapies have to undergo.
Oncologists have been refining those monitoring protocols to enable more patients to bypass inpatient stays, such as giving them their own tools to monitor symptoms as well as preventive treatments. A drug with reduced side effects could have an edge, however.
AbbVie’s trial enrolled 421 people with multiple myeloma, and randomized half to get etentamig. Independent trial monitors detected a significant difference between the two groups at a pre-planned interim checkpoint, prompting investigators to unblind the trial, leaving 393 people evaluable at an average of 11 months after trial entry.
On efficacy, etentamig reduced the risk of progression or death by 60% compared with standard therapies, and stimulated a response in 74% of the enrollees who got it, significantly more than the 46% of those on standard therapies who responded, AbbVie said.
On safety, 28% got CRS in the etentamig group, and only one got ICANS. By comparison, in clinical trials nearly three-quarters of Tecvayli patients got CRS, along with more than half of people who received Pfizer’s Elrexfio and 46% of those who got Regeneron’s Lynozyfic. Most participants in AbbVie’s trial who developed CRS also only experienced a mild form of the immune response.
The profile gives etentamig “the potential to provide access across a range of treatment settings beyond specialized treatment centers and into outpatient and community-based settings,” said Peter Voorhees, a trial investigator and chief of the plasma cell disorders division at Atrium Health Levine Cancer Institute, in a statement provided by AbbVie.
AbbVie said it will discuss the trial results with regulators and present the data later this month at the International Myeloma Society Annual Meeting.
Facts Only
AbbVie developed a bispecific antibody called etentamig for multiple myeloma.
The Phase 3 trial included 421 participants, 393 of whom were evaluable.
Participants had progressed on two or more prior lines of therapy.
Etentamig reduced the risk of progression or death by 60% compared to standard therapies.
The response rate for etentamig was 74%, while standard therapies were 46%.
28% of the etentamig group experienced cytokine release syndrome (CRS).
One participant in the etentamig group experienced ICANS.
Tecvayli recorded $462 million in sales in the first half of 2026.
Trial data will be presented at the International Myeloma Society Annual Meeting.
Etentamig binds simultaneously to diseased tumor cells and T cells.
Executive Summary
AbbVie has announced positive Phase 3 clinical trial results for etentamig, a bispecific antibody designed to treat multiple myeloma in patients who have progressed after two or more prior lines of therapy. The drug met its primary endpoint, demonstrating a 60% reduction in the risk of progression or death compared to standard treatment regimens, with a response rate of 74% versus 46% for the control group.
A significant differentiator for etentamig is its safety profile. The trial reported lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to existing bispecific antibodies from Johnson & Johnson, Pfizer, and Regeneron. Because these serious immune responses are less frequent and generally milder, there is potential for the drug to be administered in community oncology centers rather than specialized inpatient facilities. The company intends to discuss these findings with regulators and present full data at the International Myeloma Society Annual Meeting.
Full Take
The strongest version of this narrative is that etentamig represents a meaningful evolution in immunotherapy—not necessarily by increasing raw efficacy, but by lowering the "barrier to entry" for patient care. By reducing the severity of CRS and ICANS, the treatment shifts from a high-risk hospital procedure to a manageable community-based therapy.
However, the presentation of this data relies heavily on a specific comparison framework. The primary persuasive engine is the juxtaposition of AbbVie’s internal trial results against the historical trial data of competitors (Tecvayli, Elrexfio, and Lynozyfic). This creates a narrative of superiority based on safety margins that may be influenced by different trial designs or patient populations. The reliance on AbbVie's own reporting to validate the safety advantage over rivals constitutes a strategic use of proprietary data to frame market positioning.
Patterns detected: ARC-0043 Authority Game
The underlying paradigm is the "commoditization of immunotherapy." The transition from CAR-T (highly bespoke, expensive, high-risk) to bispecific antibodies (off-the-shelf, lower risk) reflects a drive toward scalability. The benefit is increased patient access; the cost is a shift toward a high-volume pharmaceutical model where "safety" is marketed as a logistical advantage for clinics (reduced monitoring costs) as much as a clinical advantage for patients.
If this were a coordinated influence campaign, the playbook would involve leaking "superior safety" metrics just before a major industry conference to manipulate stock sentiment and preemptively capture the "community care" market segment. The current content does not match this pattern; it is a standard corporate announcement of clinical success.
Bridge Questions:
1. How do the baseline characteristics of the etentamig trial population differ from those in the Tecvayli or Elrexfio trials?
2. Does a "milder" form of CRS actually reduce the necessity for inpatient monitoring, or is the distinction clinically marginal?
3. What is the long-term durability of the response compared to the established first-movers in this drug class?